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Background: Lowering the temperature setting in the heating device during continuous venovenous
hemofiltration (CVVH) is an option. The purpose of this study was to determine the effects on body temperature
and hemodynamic tolerance of two different temperature settings in the warming device in patients treated with
CVVH.
Methods: Thirty patients (mean age: 66.5 years; mean SAPS 2: 55) were enrolled in a prospective crossover
randomized study. After a baseline of 2 h at 38°C, the heating device was randomly set to 38°C (group A) and 36°C
(group B) for 6 h. Then, the temperatures were switched to 36°C in group A and to 38°C in group B for another
6 h. Hemodynamic parameters and therapeutic interventions to control the hemodynamics were recorded.
Results: There was no significant change in body temperature in either group. During the first 6 h, group B
patients showed significantly increased arterial pressure (p= 0.01) while the dosage of catecholamine was
significantly decreased (p= 0.04). The number of patients who required fluid infusion or increase in catecholamine
dosage was similar. During the second period of the study, hemodynamic parameters were unchanged in both
groups.
Conclusions: In patients undergoing CVVH, warming of the substitute over 36°C had no impact on body
temperature. We showed that setting the fluid temperature at 36°C for a period of time early in the procedure is
beneficial in terms of increased mean arterial pressure and decreased catecholamine infusion dosage.
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The thermal consequence of renal replacement therapies
varies with the technique used. During IHD, core
temperature (CT) increase is due to: 1)the direct delivery
of thermal energy by the extracorporeal circuit that
overcomes the external energy losses; 2) the increase in
thermogenic metabolic rate as a consequence of bio-
logical mechanisms induced by the bioincompatibility of
the circuit materials; and 3) decreased dissipation of heat
caused by cutaneous vasoconstriction compensating for
ultrafiltration-related hypovolemia [1-4]. As summarized
in a meta-analysis [5], several studies demonstrated the
beneficial effect of dialysate cooling on vascular response,* Correspondence: r.robert@chu-poitiers.fr
1Department of Critical Care Medicine, University of Poitiers, CHU, Poitiers
F86000, France
2INSERM Unit U1082, University of Poitiers, CHU, Poitiers F86000, France
Full list of author information is available at the end of the article
© 2012 Robert et al.; licensee Springer. This is a
Attribution License (http://creativecommons.or
in any medium, provided the original work is pwith a reduction of intradialytic hypotensive episodes and
higher postdialysis mean arterial pressure. As a conse-
quence, it is now recommended to decrease the
temperature of the dialysate to improve hemodynamic tol-
erance of IHD [6].
In intensive care unit (ICU) patients with multiple organ
failure, continuous renal replacement therapies (CRRT)
are frequently used. During CRRT, the consequence of
heat loss in ECC is a reduced body temperature, which in
turn may activate compensatory mechanisms, such as skin
vasoconstriction and endogenous heat production [7].
Hypothermia can theoretically induce detrimental effects
[8,9], such as uncontrolled, intense shivering, uncoordin-
ated movements, pain and discomfort, decreased insulin
secretion and peripheral sensitivity, and left shift in the
oxyhemoglobin dissociation curve, which may impair O2
extraction rate. Thus, manufacturers included in then Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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blood returning to the patient aiming at counteracting the
heat loss, and current practice for CRRT is to warm up
substitution fluids to avoid significant hypothermia [10].
However, such warming may alter vascular reactivity and
induce hypotension [11]. The optimal target temperature
remains unknown, and there are no guidelines for the set-
ting of the heating device during hemofiltration, particu-
larly in septic patients.
In patients with chronic kidney injury receiving hemo-
filtration, it has been reported that cooling the circuit may
increase vascular resistances and improve hemodynamic
tolerance [12,13]. However, few studies have analyzed the
temperature variations in ICU patients treated with con-
tinuous renal therapies. Manthous et al. [14] reported
major hypothermia associated with shivering and vasocon-
striction in a short series of septic patients. Other studies
failed to demonstrate any deleterious hemodynamic effect
of hypothermia in patients treated with CVVH [15,16].
More recently, Rokyta et al. demonstrated in patients trea-
ted with CVVH that cooling over a short period of time
was associated with significant decrease in heart rate, car-
diac output, systemic oxygen delivery and consumption,
as well as increase of the mean arterial pressure without
significant alteration of energetic balance [17]. Thus, fur-
ther investigation is of importance to determine the opti-
mal recommended temperature in ICU patients treated
with CVVH.
The goal of this study was to examine the eventual
benefits of temperature changes in the fluid substitute
on hemodynamic tolerance in ICU patients treated with
CVVH.
Methods
In vitro validation study
Because it was not possible to monitor the real
temperature variation in the circuit induced by the dif-
ferent levels of heating device setting, in a preliminary
phase, the hemofiltration circuit was set in vitro, using
CRRT machine a (Multifiltrate generator, Fresenius
medical Care; Bad Homburg, Germany) and polysulfone
membrane (Ultraflux AV1000S, Fresenius medical Care;
Bad Homburg, Germany). Access and return lines were
connected to a 2,000-ml saline bag placed on a heating
device constantly set at 39°C. Blood flow was set to
100 ml per min and ultrafiltration (UF) rate (2000 ml per
h) was continuously compensated with saline at the same
rate. A thermistor sensor (Hanna Instruments; NJ, USA)
was inserted inside the bubble trap close to the tip of
venous line. Temperature of the heating device incorpo-
rated to the Multifiltrate generator was first set to 36°C
then to 38°C and back to 36°C.
Two experiments were successively performed. After
30 min of stability, the measured temperature was 32°Cin both cases while the heating device was set to 36°C.
After setting the heating device to 38°C, and in the
subsequent 30 min, the temperature increased to 32.8°C
in the first experiment and 32.7°C in the second. Turn-
ing back the heating device to 36°C, the measured
temperature decreased to 32°C in both experiments.
Thus, moderate, but significant, temperature variations
were induced using two different levels of temperature
setting in the warming device suggesting that true blood
temperature differences may be achieved in vivo with
similar heating device settingPatient study
Patient recruitment
Medical or surgical ICU patients were recruited for this
monocenter pilot crossover randomized study.Sample size
In the absence of data from literature allowing deter-
mination of the frequency of hypotension during the
first 6 h of hemofiltration, this study was a pilot study
involving 30 patients (15 in each group). The duration
of the study was 12 h.Inclusion and exclusion criteria
Patients with acute renal failure and multiple organ fail-
ure treated with CVVH for at least 6 h were included.
The weight loss was to be lower than 50 ml per hour to
be included in the study. The choice of CVVH as re-
placement technique was determined by the physician in
charge of the patient. Hemodynamic failure was defined
by the necessity to administer catecholamine infusion after
optimal fluid infusion (norepinephrine > 0.1 μg/kg/min;
epinephrine >0.1 μg/kg/min or dobutamine >10 μg/kg/
min) to achieve a mean arterial pressure higher than
65 mmHg. Patients admitted after cardiac resuscitation
and patients with a high bleeding risk without possibility to
use heparin as anticoagulation in the circuit were not
included in the study. Other patient exclusion criteria were:
existing treatment with hemodiafiltration (CVVHDF);
major hemodynamic instability defined by the necessity of
increased catecholamine infusion dosage or to infuse fluid
challenge to control arterial pressure within the first 2 hours
following the start of CVVH; tympanic temperature <36°C
before randomization.Consent - ethics
Institutional approval was obtained from the Ethical
Committee (Comité de Protection des Personnes CHU
Poitiers, 86021 Poitiers Cedex, France; Chairperson Dr
Louis Lacoste; N°2007.A00681-52). Written, informed
consent was obtained from the patients or next of kin.
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The order of the sessions was randomized by using a
randomization list.
Instruments - machines used
CVVHF was set up following a standardized institutional
protocol. Briefly, a double-lumen, 13-French catheter was
positioned in the femoral (20 or 25 cm of length) or in-
ternal jugular vein (20 cm). UF rate was set to 35 ml/kg/h
with a corresponding adapted blood flow between 150 and
200 ml/min. Fluid replacement was administered before
(1/3) and after dilution (2/3). Multifiltrate generator (Fre-
senius Medical Care; Bad Homburg, Germany) and poly-
sulfone membrane (Ultraflux AV1000S, Fresenius Medical
Care) were used. Anticoagulation was performed with
unfractionated heparin targeting activated coagulation
time around 1.5 compared with control. The temperature
of the heating device incorporated to the Multifiltrate gen-
erator and placed on the pre and post-dilution substrate
line was initially set to 38°C in all patients.
Method - procedures
A schematic of the study is displayed in Figure 1.Two
hours following the start of CVVH (baseline), the
patients were randomized in two groups: in group A,
the heater was set to 38°C during 6 h (H1-H6) and then
to 36° for the next 6 h (H7-H12); conversely, in group B
the heater was set initially to 36°C and then to 38° for
similar periods of time.
Data collected
Tympanic temperature (Genius 2; Codivien-Nelcor and
Puritan Benett; Boulder, CO), arterial pressure, and heart
rate were monitored hourly from H1 to H12. Lactate
levels and blood gas analysis were determined at H0,
H6, and H12. The main judgement criteria were the oc-
currence of hemodynamic alteration during the consid-
ered 6 h period of time, defined as follows: decrease of
mean arterial pressure (MAP) > 20% from initial value or
the necessity of any therapeutic intervention, fluid infu-
sion, or increase of catecholamine infusion dosage.
After the 12th hour, the temperature setting left at the
liberty of the physician in charge of the patient. If the
lifespan of the circuit was below 6 h, the patient was
excluded from the study. If the lifespan of the circuit
was between 6 and 12 h, patient data were included in a
secondary analysis.
Statistical analysis
Qualitative data were compared using chi-squared test
or Fisher exact test when appropriate. Continuous data
were compared between groups using nonparametric
Mann-Whitey test. Intragroup comparisons of continu-
ous data were performed using a nonparametric Wilcoxontest for repeated measures. A p value < 0.05 was consid-
ered significant.
Results
Among 47 patients treated with CVVH in our unit from
August 2008 to may 2009, 17 were not included in the
study (6 were too hemodynamically instable, 2 refused
to participate, 7 had CVVH circuit dysfunction or clot-
ting before H6 (2 before randomization and 5 early after
randomization), and 2 had tympanic temperature below
36°C before randomization). The remaining 30 patients
(21 males and 9 females) were included in the study
(Figure 1). The clinical characteristics of these patients
are summarized in Table 1.
The mean tympanic temperature before the start of
CVVH was 37.2 ± 1.4°C in group A and 37.94±1.1°C in
group B. During the 2 hours of stabilization, the tempera-
tures significantly decreased to 36.5±0.7°C and 36.5±0.9°C
respectively. The temperature then remained unchanged
for the duration of the study: 36.3±0.5°C in group A and
36.4± 0.5°C in group B at H6; then 36.7±1.1°C in group A
and 36.1±0.7°C in group B at H12.
During the first 6 h, group B patients significantly
increased their arterial pressure (p= 0.01), whereas in
these patients the dosage of catecholamine infusion was
significantly decreased (p= 0.04; Table 2). Conversely in
group A patients, there was no significant change in
arterial pressure or catecholamine infusion dosage
(Table 2). The number of patients requiring fluid infu-
sion or increased catecholamine dosage was similar be-
tween groups (Table 2).
Among the 30 patients, filter thrombosis occurred in 8
cases between H7 and H12 (5 patients from group A and
3 from group B), thus only 22 patients could complete the
crossover study. The characteristics of the patients during
the second period of time are summarized in Table 3.
There was no difference observed between H7 and H12 in
hemodynamic parameters, including lactate plasma level,
or in therapeutic interventions.
Discussion and conclusions
Only a few studies have systematically investigated
temperature changes during CRRT and evaluated their
relationship to hemodynamics in ICU patients [14-17].
In one of these studies, marked hypothermia induced by
CRRT led in some patients to shivering, profound per-
ipheral vasoconstriction, and immune system dysfunc-
tion [14]. Yagi et al. reported that patients experienced
temperature <35.5°C in 31 of the 67 of the CVVH ses-
sions without deleterious effect of hypothermia [16]. In
this latter study, there was no heating device within the
circuit. In our study, the tympanic temperature rapidly
decreased in both groups after the start of hemofiltra-
tion. Only two patients had temperature <35.5°C and
Patients treated with CVVH n=47  
Exclusions 
  Hemodynamically unstable: n=6  
  Refusal to participate : n=2  
  Early clotting of the circuit n=2  
  Tympanic Temperature < 36°C n=2  




Group  B 
temp 36°C 
n=14 
Period 1 : H1- H6 
Period 2 : H7-H12 
clotting of the circuit n=5 clotting of the circuit n=3 
n=11 n=11 
Figure 1 Flow chart of the study. Temp= temperature level set in the heating device of hemofiltration.
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specified in the protocol, and no patient had temperature
<35.5°C during the study period of the protocol. There
were no tympanic differences for either temperature set-
ting in the heating device (36°C or 38°C). However, be-
cause the heating device was placed on the infusate line,
persisting energy transfer on the remaining part of the
tubing may have attenuated the effect of the warming. We
did not measure energy transfer in the circuit directly, but
our in vitro experiment demonstrated a potential differ-
ence of 0.7°C to 0.8°C close to the venous return site of
the circuit. This decrease was probably too low to induce
significant differences in tympanic temperature of the
patients. In the study byRokyta et al. despite induced high
variations in temperature setting, only moderate change
in cutaneous temp (0.9°C) and limited CT (1.3°C) were
observed [17].
In chronic renal failure patients, several studies reported
a significant reduction in the frequency of hypotensive epi-
sodes during hemofiltration [11-13], but in ICU patients
the impact of temperature variation induced by CVVH on
hemodynamic parameters is not established. Matamis et al.reported an increase of MAP and SVR only in patients
who became hypothermic during hemofiltration [15]. Con-
versely, in one retrospective study, MAP was similar in
hypothermic and nonhypothermic patients [16]. Finally, in
a study involving nine patients submitted to a dramatic
cooling of the circuit from 39°C to 20°C, there was a sig-
nificant increase of vascular resistance and mean arterial
pressure, whereas heart rate, cardiac output, systemic oxy-
gen delivery, and consumption decreased [17]. However, in
this study, hypothermia lasted only 2 hours, and potential
deleterious effect could be observed.
Our study is the first prospective, controlled study to
show a significant increase of SAP and MAP in a group
of patients treated with CVVH set at a low temperature
(36°C) for 6 h after a baseline period of 2 h at 38°C. This
increase was associated with a significant decrease in
catecholamine infusion dosage, indicating improvement
of hemodynamic status. The suspected mechanisms for
cardiovascular tolerance during cold HD are a greater
catecholamine release, an increase in vascular peripheral
resistances, and in venous tone [18]. In our practice,
noninvasive investigation are privileged to manage







Age (yr) 66.5 [10.3] 68.3 [12.3] 65.2 [7.3]
Sex male (no.patients) 21 12 9
SAPS 2 on admission 55.0 [14.1] 60.5 [12.0] 50.0 [13.9]
SOFA on admission 10.6 [4.6] 12.8 [3.8] 8.0 [3.8]
Main diagnosis (no. patients)
Severe sepsis 20 12 8
Abdominal 7 6 1
Pneumonia 6 2 4
Miscellaneous 7 4 3
Cardiac surgery 4 1 3
Respiratory failure 2 1 1
Mesenteric ischemia 2 1 1
Temperature (°C) at ICU admission 37.4 [1.2] 37.4 [1.1] 37.4 [1.4]
SAP mmHg H1 117 [30] 118 [26] 113 [26]
DAP mmHg H1 58 [11] 58 [13] 58 [9]
MAP mmHg H1 75 [12.5] 77 [15] 71 [7]
Heart rate (beat/min) H1 98 [19] 94 [16] 103 [23]
Mechanical ventilation (n of patients) 27 16 11
Creatinine before onset (μmol/L) 267 [129] 257 [84] 293 [164]
Diuresis < 100 ml/6 h before inclusion (no. patients) 20 12 8
Hydrocortisone treatment (no. patients) 17 9 8
Norepinephrine (no. patients) 23 12 11
Dobutamine (no. patients) > 5 μg/kg/h 5 2 3
Epinephrine (no. patients) 3 2 1
Lactate (mmol/L) 3.7 [3.6] 4.1 [3.4] 3.2 [2.3]
Values are expressed as mean [SD] or median (interquartile range); SAP systolic arterial pressure, DAP diastolic arterial pressure, MAP mean arterial pressure H0
time of start of hemofiltration, SAPS simplified acute physiologic score SOFA score of organ failure.
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not systematically performed in our patients, thus the
increase of vascular resistances during the 36°C period
could not be demonstrated. Interestingly and contrasting
with other studies, improvement of hemodynamic con-
dition was not associated with differences in core
temperature. This is in accordance with a study per-
formed in chronic patients, showing that postdilution
hemodiafiltration with a 2.5 l.h-1 volume exchange was
associated with a better blood pressure stability com-
pared with hemodiafiltration with low-volume exchange
of dialysis without cooling, whereas CT was not decreased
[4]. This was explained by the increased loss of extracor-
poreal energy, which may prevent cutaneous vasodilation
[11].
There was no significant hemodynamic difference dur-
ing the second period of the crossover experiment. On
the one hand, maintenance of elevated SAP and MAP as
well as reduced catecholamine infusion dosage suggestthat this short period of hypothermia induces long-term
benefits for the patient without the need for prolonged
hypothermia and associated risks. On the other hand,
the absence of hemodynamic difference during the sec-
ond period of the crossover experiment in group A
(lowered to 36°C at H6) suggests that the beneficial
hemodynamic effects of the 36°C compared with the
38°C temperature setting is not straightforward. Timing
the hypothermic period early in the treatment seems to
be beneficial compared with a later hypothermic period.
However, specific effect of temperature variation during
a prolonged observation period may be blunted by many
factors that may interfere with the hemodynamic status
of a critically ill patient. Additionally, the reduced num-
ber of patients of the second period due to hemofilter
dysfunction has probably limited the statistical power of
the study.
Furthermore, the beneficial effect of cooling on the life
span of the extracorporeal circuit has been suggested
Table 2 Hemodynamic variations and therapeutic interventions from H1 to H6
Group A Group B P intergroup
Period 1 temperature 38°C Period 1 temperature 36°C
n= 16 n=14
H1 H6 H6-H1 P Intra-
group
H1 H6 H6-H1 P Intra-
group
H6-H1
SAP mmHg 118 [26] 118 [26] 0.2 [18.9] 0.73 113 [26] 125 [20] 12.3[4.4] 0. 01 0.06
DAP mmHg 58 [13] 60 [11] 1.4 [9] 0.65 58 [9] 65 [10] 6.3 [10.6] 0.055 0.28
MAP mmHg 77 [15] 78 14] 1.2 [11.4] 0.67 71 [7] 80 [12] 8.9 [11] 0.01 0.08
HR beat/min 95 [16] 92 [18] −3 [5.9] 0.06 103 [23] 97 [28] −5.5 [28.3] 0.49 0.86
Lactates (mmol/L) 4.1 [3.4] 4.9 [4.5] 0.4 [2.2] 0.58 3.2 [2.3] 2.6 [2.0] 0.1 [0.3] 0.31 0.2
Nep dosage μg/kg/min 0.47 [1.19] 0.47 [1.33] 0.013 [0.2] 0.72 0.93 [0.81] 0.62 [0.56] −0.55 [0.3] 0.04 0.15
Increase of CA dose (no. patients) 6 4
Decrease of CA dose (no. patients) 6 7
Fluid infusion (no. patients) 5 2
Total volume infused (ml) 3500 2500
Therapeutic action (no. patients) 8 5
Values are expressed as mean [SD] or median (interquartile range); SAP systolic arterial pressure, DAP diastolic arterial pressure, MAP mean arterial pressure, Nep
norepinephrine, CA catecholamine. Therapeutic intervention: fluid infusion or increase dosage of catecholamine. P intragroup: H6 vs. H1.
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temperature variation period and the limited number of
patients did not allow evaluation of the impact of mod-
est hypothermic temperature on the potential reduction
in extracorporeal clotting and we did not evaluate the
consequences of the two regimen of temperature on
blood coagulation tests.
Our study has several limitations: 1) tympanic temperature
measure may not precisely indicate CT, and the absence ofTable 3 Hemodynamic variations and therapeutic interventio
Group A
Period 2 Temp 36°C
n= 11
H7 H12 H12-H6 P
g
SAP mmHg 124 [21] 125 [18] 1.1 [21.1] 0
DAP mmHg 62 [12] 58 [10] −3.5 [10.7] 0
MAP mmHg 79 [15] 79 [11] −0.9 [12.3] 0
HR beat/min 88 [16] 89 [12] 1.4 [12.3] 0
Lactates (mmol/L) 4.9 [5.7] 5.6 [6.8] 0.6 [1.4] 0
Nep dosage μg/kg/min 0.76 [1.01] 0.81 [1.13] 0.05 [0.3] 0
Increase of CA dose (no. patients) 2
Decrease of CA dose (no. patients) 4
Fluid infusion (n of patients) 3
Total volume infused (ml) 3500
Therapeutic action (no. patients) 3
Values are expressed as mean [SD] or median (interquartile range); SAP systolic arte
catecholamine, Nep norepinephrine. Therapeutic action: fluid infusion or increase dbody temperature difference might be related to the lack of
accuracy of the technique [20]. However, there was no
intraindividual variation of temperature for the duration of
the study; 2) the duration of the study periods may have
been too short for the evaluation of the hemodynamic
consequences of these two setting regimens; 3) better
temperature setting for the heating device (e.g., 39°C vs.
36°C) might have been more efficient to evidence
hemodynamic differences. However, we chose these levelsns from H7 to H12
Group B P intergroup




H7 H12 H12-H7 P Intra-
group
H12-H7
.66 121 [27] 122 [25] 1.5[12.8] 0.48 0.07
.45 60 [5] 64 [10] 3.7 [10] 0.18 0.16
.88 80 [10] 83 [13] 2.5 [9.9] 0.33 0.53
.99 105 [23] 102 [23] −2.8 [6.4] 0.2 0.69
.33 2.2 [1.6] 2.4 [1.9] 0.2 [0.3] 0.21 0.64






rial pressure, DAP diastolic arterial pressure, MAP mean arterial pressure, CA
osage of catecholamine.
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even though the thermal energy involved mechanisms are
different, as we indicated; 4)finally, only a limited number
of patients were enrolled in this study. However, this num-
ber was similar or higher than in most of the studies per-
formed on the effect of temperature variation in ICU
patients undergoing CRRT.
In conclusion, our study suggests that warming the
infusate over 36°C has no impact on body temperature
and may not be indicated in critically ill patients under-
going CVVH to limit heat loss. We show that setting the
fluid temperature at 36°C in CVVH for a short period of
time at the beginning of the treatment increased mean
arterial pressure while allowing for a decrease in cat-
echolamine infusion dosage. We believe this pilot study
warrants an investigation involving a larger number of
patients to confirm these findings.
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